Electronic radiation therapy set for the US
This article was originally published in Clinica
Xoft is developing an electronic brachytherapy system designed to offer doctors a non-radioactive, isotope-free alternative to traditional brachytherapy. The Axxent technology, which mimics the behaviour of the radioactive isotope, iridium-192, is currently pending FDA 510(k) approval for the treatment of breast cancer and is expected to reach the US market by the end of 2005, the Freemont, California firm told Clinica.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.